DAV132: New Results Published in AAC

DAV132: New Results Published in AAC


Retour vers la page actualités

DAV132: New Results Published in AAC

A new article published in August together with our academic collaborators from University of Paris Diderot (Antimicrob Agents Chemother; 2013 Aug 19), studies the effectiveness of oral DAV131 (a form of DAV132 optimized for rodents) in preventing colonization of a Cefotaxim resistant Klebsiella pneumonia strain (PUG-2) in mice when used in conjunction with Cefotaxim (CTX).  Grall’s study shows that DAV131 helps to combat the excess  antibiotics excreted into the intestinal tract and minimalize the disruption to the indigenous microflora, which might in turn reduce colonization by resistant strains of bacteria during antibiotic treatments.

http://www.ncbi.nlm.nih.gov/pubmed/23959311